[go: up one dir, main page]

CL2012003054A1 - Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. - Google Patents

Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.

Info

Publication number
CL2012003054A1
CL2012003054A1 CL2012003054A CL2012003054A CL2012003054A1 CL 2012003054 A1 CL2012003054 A1 CL 2012003054A1 CL 2012003054 A CL2012003054 A CL 2012003054A CL 2012003054 A CL2012003054 A CL 2012003054A CL 2012003054 A1 CL2012003054 A1 CL 2012003054A1
Authority
CL
Chile
Prior art keywords
antibody
ang
prevention
nucleic acid
pharmaceutical composition
Prior art date
Application number
CL2012003054A
Other languages
English (en)
Inventor
Anita Kavlie
Christian Klein
Joerg Thomas Regula
Werner Scheuer
Ulrich Brinkmann
Remko Albert Griep
Klaus Kaluza
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012003054A1 publication Critical patent/CL2012003054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos contra la angiopoyetina 2 humana (ANG-2); composición farmacéutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevención de metástasis; ácido nucleico que codifica dicho anticuerpo; vector de expresión.
CL2012003054A 2008-12-16 2012-10-30 Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. CL2012003054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021835 2008-12-16

Publications (1)

Publication Number Publication Date
CL2012003054A1 true CL2012003054A1 (es) 2012-12-14

Family

ID=40585738

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001285A CL2011001285A1 (es) 2008-12-16 2011-05-31 Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003054A CL2012003054A1 (es) 2008-12-16 2012-10-30 Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011001285A CL2011001285A1 (es) 2008-12-16 2011-05-31 Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Country Status (33)

Country Link
US (12) US8133979B2 (es)
EP (1) EP2379592B1 (es)
JP (2) JP5559191B2 (es)
KR (2) KR101381012B1 (es)
CN (3) CN102746400B (es)
AR (2) AR074756A1 (es)
AU (1) AU2009328613B2 (es)
BR (2) BR122013022089B1 (es)
CA (2) CA2744624C (es)
CL (2) CL2011001285A1 (es)
CR (2) CR20110321A (es)
CY (1) CY1116264T1 (es)
DK (1) DK2379592T3 (es)
EC (2) ECSP11011139A (es)
ES (1) ES2534635T3 (es)
HR (1) HRP20150439T1 (es)
HU (1) HUE024545T2 (es)
IL (2) IL213039A (es)
MA (1) MA32876B1 (es)
MX (1) MX2011005908A (es)
MY (2) MY155654A (es)
NZ (2) NZ592856A (es)
PE (2) PE20120551A1 (es)
PH (1) PH12013502192B1 (es)
PL (1) PL2379592T3 (es)
PT (1) PT2379592E (es)
RU (2) RU2569107C2 (es)
SG (1) SG172216A1 (es)
SI (1) SI2379592T1 (es)
TW (2) TWI396549B (es)
UA (2) UA105151C2 (es)
WO (1) WO2010069532A1 (es)
ZA (2) ZA201103990B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102221615A (zh) * 2011-03-31 2011-10-19 广州华灿医药科技有限公司 一种基于Angiogenin检测的双抗夹心ELISA方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
CN103958543B (zh) 2011-09-30 2016-12-14 达纳-法伯癌症研究所股份有限公司 治疗肽
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
KR20150013188A (ko) * 2012-05-24 2015-02-04 에프. 호프만-라 로슈 아게 다중특이적 항체
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014108854A1 (en) * 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
AU2014228502A1 (en) 2013-03-15 2015-08-20 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
EP3381940B1 (en) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
BR112016007112A2 (pt) * 2013-12-20 2017-09-19 Hoffmann La Roche Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
US10279021B2 (en) 2014-03-14 2019-05-07 Dana-Faber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
US9957333B2 (en) * 2014-04-17 2018-05-01 Case Western Reserve University Anti-CEP antibody or fragment thereof
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
KR102349370B1 (ko) 2014-05-26 2022-01-10 삼성전자주식회사 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2964470A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
KR20170082594A (ko) * 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
SG10201906859PA (en) * 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
US10167334B2 (en) * 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
HK1254093A1 (zh) 2015-08-14 2019-07-12 Allergan, Inc. 仅有重链的pdgf抗体
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
WO2018175752A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
CA3131250A1 (en) * 2019-02-25 2020-09-03 Pharmabcine Inc. Anti-ang2 antibody and use thereof
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
EP4183802A4 (en) * 2020-06-22 2024-11-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-ANG-2 ANTIBODY AND ITS USE
WO2022028563A1 (en) * 2020-08-07 2022-02-10 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
AU2021361108A1 (en) 2020-10-15 2023-05-25 F. Hoffmann-La Roche Ag Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
JP2025532635A (ja) * 2022-09-19 2025-10-01 ソノマ バイオセラピューティクス， インコーポレイテッド 制御性ｔ細胞を標的化して化膿性汗腺炎を治療するためのシトルリン化抗原特異的キメラ抗原受容体
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
RU2277411C1 (ru) * 2004-12-15 2006-06-10 Ольга Алексеевна Кост Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
CA2799802A1 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
ATE521638T1 (de) * 2004-12-21 2011-09-15 Medimmune Ltd Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
NZ569787A (en) 2005-12-15 2011-07-29 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
AU2007211829C9 (en) * 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
EP2247305A4 (en) * 2008-01-28 2012-11-14 Medimmune Ltd STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
RS62509B1 (sr) * 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti

Also Published As

Publication number Publication date
PH12013502192A1 (en) 2015-10-12
IL226350A0 (en) 2013-06-27
US9073986B2 (en) 2015-07-07
ECSP13011139A (es) 2014-10-31
CN103739709B (zh) 2016-08-24
CN102746400B (zh) 2015-12-16
HK1195775A1 (zh) 2014-11-21
PL2379592T3 (pl) 2015-07-31
JP5814317B2 (ja) 2015-11-17
PH12013502192B1 (en) 2015-10-12
MX2011005908A (es) 2011-06-20
CA2744624C (en) 2018-01-02
CN103739709A (zh) 2014-04-23
US20230227543A1 (en) 2023-07-20
KR101445518B1 (ko) 2014-10-01
AU2009328613A1 (en) 2010-06-24
WO2010069532A8 (en) 2012-05-10
US20120141500A1 (en) 2012-06-07
SG172216A1 (en) 2011-07-28
TWI396549B (zh) 2013-05-21
BR122013022089A2 (pt) 2019-05-28
WO2010069532A1 (en) 2010-06-24
HUE024545T2 (hu) 2016-01-28
IL226350A (en) 2016-10-31
JP2012511897A (ja) 2012-05-31
RU2011129204A (ru) 2013-01-27
JP5559191B2 (ja) 2014-07-23
US20180282404A1 (en) 2018-10-04
ZA201103990B (en) 2016-01-27
PE20140814A1 (es) 2014-07-10
CY1116264T1 (el) 2017-02-08
US20170029493A1 (en) 2017-02-02
MY155654A (en) 2015-11-13
AR074756A1 (es) 2011-02-09
CR20130418A (es) 2013-10-04
PT2379592E (pt) 2015-03-24
MY158438A (en) 2016-10-14
TW201026328A (en) 2010-07-16
CA2744624A1 (en) 2010-06-24
CN102257008A (zh) 2011-11-23
ECSP11011139A (es) 2011-07-29
EP2379592B1 (en) 2015-02-11
US8361747B2 (en) 2013-01-29
NZ592856A (en) 2012-06-29
JP2014000089A (ja) 2014-01-09
IL213039A0 (en) 2011-07-31
SI2379592T1 (sl) 2015-06-30
MA32876B1 (fr) 2011-12-01
CR20110321A (es) 2011-07-14
PE20120551A1 (es) 2012-05-21
NZ600005A (en) 2012-08-31
US20140065707A1 (en) 2014-03-06
CA2916481A1 (en) 2010-06-24
US20200262904A1 (en) 2020-08-20
US20100159587A1 (en) 2010-06-24
TW201322996A (zh) 2013-06-16
US20150284457A1 (en) 2015-10-08
US20120142091A1 (en) 2012-06-07
CA2916481C (en) 2018-05-15
US20140065151A1 (en) 2014-03-06
US8399626B2 (en) 2013-03-19
US8133979B2 (en) 2012-03-13
US20210388071A1 (en) 2021-12-16
RU2569461C2 (ru) 2015-11-27
KR101381012B1 (ko) 2014-04-11
EP2379592A1 (en) 2011-10-26
KR20110084536A (ko) 2011-07-25
BR122013022089B1 (pt) 2021-10-13
HRP20150439T1 (hr) 2015-05-22
RU2569107C2 (ru) 2015-11-20
RU2013140625A (ru) 2015-03-10
DK2379592T3 (en) 2015-03-02
UA105151C2 (uk) 2014-04-10
ES2534635T3 (es) 2015-04-27
AR092487A2 (es) 2015-04-22
ZA201307297B (en) 2019-07-31
US20130156789A1 (en) 2013-06-20
US9340609B2 (en) 2016-05-17
AU2009328613B2 (en) 2013-09-05
KR20130103822A (ko) 2013-09-24
BRPI0923434A2 (pt) 2017-09-19
CN102746400A (zh) 2012-10-24
US9109027B2 (en) 2015-08-18
TWI482631B (zh) 2015-05-01
HK1172349A1 (zh) 2013-04-19
UA103912C2 (uk) 2013-12-10
CL2011001285A1 (es) 2011-09-16
IL213039A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
CL2012003054A1 (es) Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.
CL2013000669A1 (es) Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112014026755B8 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
CL2013002828A1 (es) Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento
AR095374A1 (es) Moléculas de unión para bcma y cd3
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2008002873A1 (es) Anticuerpo anti-glipican 3/gpc3; composicion que lo comprende; agente anti-canceroso que lo comprende; acido nucleico que codifica dicho anticuerpo; celula hospedera aislada que comprende dicho acido nucleico; metodo para la preparacion de dicho anticuerpo
AR079551A1 (es) Anticuerpos anti-her3 y usos de los mismos
EA201300388A1 (ru) Соединения замещенного бензамида
BR112012020372A2 (pt) "naticorpo que se liga ao csf- 1r humano, composição farmaceutica acido nucleico vetoresde expressão, célula hospedeira e método para a produção de um anticorpo recobinante
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
UY33380A (es) Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1